When was Oak Hill Bio founded?

Oak Hill Bio was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Where is Oak Hill Bio located?

Oak Hill Bio is headquartered in Altrincham, United Kingdom.

How many employees does Oak Hill Bio have?

As of Sep 30, 2026, the latest employee count at Oak Hill Bio is 32.

Is Oak Hill Bio a funded company?

Oak Hill Bio is a funded company, having raised a total of $32.5M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Feb 01, 2022.

When was the latest funding round of Oak Hill Bio?

Oak Hill Bio's latest funding was a $***** Series A round on Jun 02, 2026, with participation from 4 investors. Its primary sector is Rare Diseases. In United Kingdom, the Rare Diseases sector has seen $153M in funding in 2026 to date.

Where does Oak Hill Bio rank among its competitors?

Oak Hill Bio ranks 10th amongst 25 active competitors, of which 8 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Oak Hill Bio, which secured $32.5M in Jun, 2026.

Who are the top competitors of Oak Hill Bio?

Oak Hill Bio's top competitors include X4 Pharmaceuticals, Forge Biologics and Krystal Biotech. Among them, Oak Hill Bio secured the most recent funding round in June, 2026.

Oak Hill Bio - 2026 Company Profile, Team, Funding & Competitors

Oak Hill Bio is a series A company based in Altrincham (United Kingdom), founded in 2021 by Josh Distler. It operates as a Developer of therapeutics to treat rare autoimmune diseases. Oak Hill Bio has raised $32.5M in funding from Balyasny Asset Management. The company has 25 active competitors, including 8 funded and 10 that have exited. Its top competitors include companies like X4 Pharmaceuticals, Forge Biologics and Krystal Biotech.

Company Details

Developer of therapeutics to treat rare autoimmune diseases. The lead candidate of the company is OHB-607 a proprietary, recombinant version of insulin-like growth factor 1 (IGF-1), for extremely premature infants. Other candidates include OHB-201, OHB-211, and OHB-301 for systemic lupus erythematosus, diabetic macular edema, and immune thrombocytopenia.

Website: oakhillbio.com
Email ID: *****@oakhillbio.com

Key Metrics

Founded Year

2021

Location

Altrincham, United Kingdom

Stage

Series A

Total Funding

$32.5M in 2 rounds

Latest Funding Round

Series A, Jun 02, 2026, $*****

Investors

Balyasny Asset Management & 4 more

Ranked

10^th among 25 active competitors

Employee Count

32 as on Sep 30, 2026

Similar Companies

X4 Pharmaceuticals & 26 more

View Oak Hill Bio's full profile

Oak Hill Bio has raised a total funding of $32.5M over 2 rounds. Its first funding round was on Feb 01, 2022. Its latest funding round was a Series A round on Jun 02, 2026 for $*****. 4 investors participated in its latest round. Oak Hill Bio has 5 institutional investors.

Here is the list of recent funding rounds of Oak Hill Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 02, 2026	6472351	Series A	4062734	6133367	6997700	5995052
Feb 01, 2022	6031605	Seed	7064640	5781244	5653685	Takeda

Access funding benchmarks and valuations. Sign up today!

View details of Oak Hill Bio's funding rounds and investors

The founders of Oak Hill Bio is Josh Distler.

Here are the details of Oak Hill Bio's key team members:

Josh Distler: Co-Founder, President, and CFO of Oak Hill Bio.

View details of Oak Hill Bio's Founder profiles and Board Members

Oak Hill Bio's employee count trend

Oak Hill Bio has 32 employees as of Sep 26. Here is Oak Hill Bio's employee count trend over the years:

Uncover Oak Hill Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Oak Hill Bio include X4 Pharmaceuticals, Forge Biologics and Krystal Biotech. Here is the list of Top 10 competitors of Oak Hill Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	X4 Pharmaceuticals 2014, Boston (United States), Public	Developer of small molecule drugs for the treatment of cancer	$58.2M	Coastlands Capital, Bain Capital Life Sciences ... & 22 others	75/100
2nd	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	72/100
3rd	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Frazier Life Sciences, Danforth Advisors & 3 others	66/100
4th	Rigel 1996, San Francisco (United States), Public	Developer of drugs for hematologic disorders, cancer, and rare immune disease	-	MidCap Financial, ProQuest Investments & 6 others	64/100
5th	Innovent Bio 2011, Suzhou (China), Public	Developer of antibody therapeutics for multiple diseases	$535M	Eight Roads Ventures, Lilly Asia Ventures ... & 24 others	62/100
6th	Dianthus Therapeutics 2019, Waltham (United States), Public	Developer of antibody therapeutics to treat rare autoimmune diseases	$100M	Fidelity Investments, 5AM Ventures & 6 others	62/100
7th	Savara Pharma 2008, Austin (United States), Public	Developer of therapeutics for rare respiratory diseases	$67.8M	Austin Technology Incubator, Bain Capital Life Sciences ... & 20 others	61/100
8th	Athos Therapeutics 2019, Torrance (United States), Series A	Developer of AI-based therapeutics for treating autoimmune diseases	$38.3M	-	59/100
9th	Terns Pharmaceutical 2017, San Mateo (United States), Acquired	Developer of therapies for treating liver disease and cancer	$208M	Lilly Asia Ventures, Deerfield & 6 others	57/100
10th	Oak Hill Bio 2021, Altrincham (United Kingdom), Series A	Developer of therapeutics to treat rare autoimmune diseases	$32.5M	Janus Henderson Investors, VenBio & 3 others	56/100